title: [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
abstract: Aberrant protein aggregation is closely linked to the molecular pathogeneses of most neurodegenerative diseases. The major components of pathological aggregates have been characterized in various neurodegenerative diseases; for example, amyloid β-protein and phosphorylated tau in Alzheimer's disease, α-synuclein in Parkinson's disease, SOD1 or TDP-43 in amyotrophic lateral sclerosis, and huntingtin in Huntington's disease. These misfolded protein aggregates play a vital role in disease initiation and progression, and they have recently been shown to have prion-like spreading or seeded aggregation properties. Immunotherapy with specific monoclonal antibodies is a promising approach to clear misfolded protein aggregates and treat various neurodegenerative diseases; it is planned for use in clinical trials in the near future.
authors.affiliation: Department of Neurology, Tokyo Metropolitan Geriatric Hospital, Japan.
authors.forename: Kazutomi
authors.initials: K
authors.lastname: Kanemaru
mesh_terms: D016229:Amyloid beta-Peptides / Q000276:immunology; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D019636:Neurodegenerative Diseases / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D017510:Protein Folding / Q000187:drug effects; D057165:Proteostasis Deficiencies / Q000175:diagnosis / Q000276:immunology / Q000628:therapy
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies